Acurx Pharmaceuticals, Inc.
For the period ended Dec 31, 2024. Filed Mar 17, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 17, 2025
ACXP$1.060.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Changes in Shareholders’ Equity
| | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | | | | | | | | | | |
| · · Common Stock · · · · · · · · · | ||||||||||||||
| | | | | | | | | Additional | | | | | | Total |
| · · · Paid-In · Accumulated · Shareholders’ | ||||||||||||||
| | | Shares | | | Amount | | | Capital | | | Deficit | | | Equity |
| Balance at January 1, 2023 | 11,627,609 | $11,628 | $45,944,478 | $(38,641,085) | $7,315,021 | |||||||||
| Share-Based Compensation | | — | | — | | 3,206,527 | | — | | 3,206,527 | ||||
| Share-Based Payments to Vendors | | 140,186 | | 140 | | 559,443 | | — | | 559,583 | ||||
| Issuance of shares of common stock and pre-funded warrants in registered direct offering, net of $456,314 cash issuance costs | | 601,851 | | | 602 | | | 3,543,010 | | — | | 3,543,612 | ||
| Issuance of shares of common stock in At-the-Market sales agreement, net of $222,161 cash issuance costs | | 680,252 | | | 680 | | | 2,399,958 | | | — | | | 2,400,638 |
| Warrant Exercise | | 682,769 | | | 683 | | | 2,218,316 | | | — | | | 2,218,999 |
| Cashless Warrant Exercise | | 4,080 | | | 4 | | | (4) | | — | | — | ||
| Pre-funded Warrant Exercise | | 731,482 | | | 731 | | | (658) | | — | | 73 | ||
| Net Loss | — | | — | | — | | (14,577,768) | | (14,577,768) | |||||
| Balance at December 31, 2023 | 14,468,229 | $14,468 | $57,871,070 | $(53,218,853) | $4,666,685 | |||||||||
| Share-Based Compensation | | — | | | — | | | 2,601,903 | | — | | 2,601,903 | ||
| Share-Based Payments to Vendors | | 353,170 | | | 353 | | | 833,327 | | — | | 833,680 | ||
| Issuance of shares of common stock in At-the-Market sales agreement, net of $209,305 cash issuance costs | | 2,150,076 | | | 2,151 | | | 6,403,606 | | — | | 6,405,757 | ||
| Warrant Exercise | | 59,211 | | | 59 | | | 210,140 | | | — | | | 210,199 |
| Net Loss | — | | — | | — | | (14,103,103) | | (14,103,103) | |||||
| Balance at December 31, 2024 | 17,030,686 | | $17,031 | | $67,920,046 | | $(67,321,956) | | $615,121 | |||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.